A scintigraphy study of PT010 in COPD patients - RD708/34000

Study identifier:D5980C00020

ClinicalTrials.gov identifier:NCT03906045

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-Dose, Gamma Scintigraphy Study to Assess the Pulmonary Deposition of Technetium-99m Radiolabelled Budesonide, Glycopyrronium and Formoterol Fumarate MDI in Patients with Moderate to Severe/Very Severe COPD.

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

No

Study drug

BGF-MDI

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 04 Apr 2019
Primary Completion Date: 05 Mar 2020
Study Completion Date: 05 Mar 2020

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Simbec Research Ltd.

Inclusion and exclusion criteria